Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems

Journal of Neural Transmission

Volumn 109, Issue 5-6, 2002, Pages 777-787

  Carlsson, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; CATECHOLAMINE; CHLORPROMAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LEVODOPA; NORADRENALIN; PRECLAMOL; RESERPINE; SEROTONIN;

ANIMAL BEHAVIOR; ARTICLE; BASAL GANGLION; BIOASSAY; COLORIMETRY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RIGIDITY; SPECTROFLUOROMETRY;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; LEVODOPA; NEUROLOGY; PARKINSON DISEASE; RESEARCH;

EID: 0036312497     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200064     Document Type: Article

References (38)

1. Adrenergic mechanisms
2. Oral L-DOPA treatment of Parkinsonism
3. Les catecholamines dans la maladie de Parkinson
4. Occurrence and distribution of dopamine in brain and other tissues
5. Der L-3,4-dioxyphenylalanin (=L-DOPA)-effekt bei der Parkinson-Akinese
6. The occurrence, distribution and physiological role of catecholamines in the nervous system
7. Physiological and pharmacological release of monoamines in the central nervous system
8. Autobiography
9. Release of adrenaline from the adrenal medulla of rabbits produced by reserpine
10. A fluorimetric method for the determination of dopamine (3-hydroxytyramine)
11. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain
12. Effect of reserpine on the metabolism of catecholamines
13. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
14. On the presence of 3-hydroxytyramine in brain
15. A new histochemical method for visualization of tissue catecholamines
16. Network interactions in schizophrenia - Therapeutic implications
17. Aromatic amino acids and modification of parkinsonism
18. Making visible the invisible (Recollections of the first experiences with the histochemical fluorescence method for visualization of tissue monoamines)
19. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems
20. Colorimetric determination of noradrenaline and adrenaline
21. Fluorescence of catecholamines and related compounds condensed with formaldehyde
22. The L-DOPA story revisited. Further surprises to be expected? The contribution of Isamo Sano to the investigation of Parkinson's disease
23. (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled study
24. Metabolism of brain dopamine in human Parkisonism: Neurochemical and clinical aspects
25. From dopamine to Parkinson's disease: A personal research record
26. Antipsychotic properties of the partial dopamine agonist(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
27. Über humorale übertragbarkeit der herznervenwirkung (I. Mitteilung)
28. Discovery of dopamine deficiency and the possibility of dopa therapy in Parkinsonism
29. Serotonin release as a possible mechanism of reserpine action
30. Serotonin as a mediator of reserpine action in brain
31. Biochemical studies of aromatic monoamines in the brain
32. Biochemistry of extrapyramidal motor system
33. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease